Batavia Biosciences Partners With VBC And MEVAC To Advance Localized Vaccine Manufacturing In Egypt

Batavia Biosciences, a leading Contract Development and Manufacturing Organization (CDMO) specializing in development and manufacturing of vaccines and viral vectors, is excited to announce a strategic collaboration with Vaccine Biotechnology City (VBC) and MEVAC, two pioneering organizations in Egypt. The partnership aims to enhance local vaccine manufacturing capabilities, focusing initially on Measles, Rubella, and Rotavirus vaccines.

This collaboration underscores Batavia Bioscience’s commitment to addressing global health inequities by transferring advanced technologies, and know-how to support sustainable vaccine production in underserved regions. Through this partnership, Batavia will license proprietary processes, analytical methods, and production systems to VBC and MEVAC, empowering them to produce high-quality vaccines locally and meet international standards.

The collaboration builds on a previously signed license agreement for Measles and Rubella vaccines, with negotiations for Rotavirus vaccines currently underway. This partnership positions Egypt as a vital player in vaccine manufacturing, contributing to greater vaccine self-reliance for the Middle East and Africa. By supporting local production, this initiative aims to ensure wider access to affordable vaccines, particularly in regions most impacted by vaccine-preventable diseases.

VBC, a biopharmaceutical company established as part of Egypt’s national strategy to localize vaccine manufacturing, is leading the effort to produce vaccines that meet global standards. MEVAC, a global leader in animal health vaccine development, brings its extensive manufacturing expertise and infrastructure to the collaboration. Both organizations are supported by the Egyptian Vaccine Manufacturers Alliance (EVMA), a national initiative driving vaccine production efforts across the country.

Batavia Biosciences’ role as a trusted CDMO involves leveraging its expertise in upstream and downstream process development, quality assurance, and regulatory compliance to accelerate vaccine production and delivery.

Ahd Hamidi, Strategic Partnership Director at Batavia Biosciences, stated: “This collaboration reflects our mission to deliver affordable and accessible vaccine solutions to regions where they are most needed. By enabling local vaccine production, we aim to empower Egypt as a critical player in the fight against preventable diseases in Africa and beyond.”

Momtaz Wasfy, Business Development Director at MEVAC/VBC, stated: “The collaboration between VBC/MEVAC and Batavia on vaccine development represents a powerful synergy that combines expertise and resources to address pressing global health challenges. By pooling combined knowledge and capabilities, VBC will accelerate the development of effective vaccines, improving access to life-saving solutions across the Middle East and Africa. Also, this partnership has the potential to enhance global health by addressing infectious diseases, reducing the burden on healthcare systems, and ensuring timely and equitable distribution of vaccines, ultimately contributing to the overall well-being of populations worldwide.”

As the collaboration progresses, Batavia, VBC, and MEVAC will continue to work closely to achieve sustainable vaccine production in Egypt. With discussions for Rotavirus vaccines advancing, the partnership is set to make a lasting impact on public health outcomes across Africa and the Middle East.

About Batavia Biosciences
Batavia Biosciences significantly contributes to ease human suffering from infectious diseases, cancer, and rare diseases by leveraging our innovative technologies and in-depth know-how. We do this for viral vaccines and viral vectors solutions at all stages of the development trajectory, from the transition into early clinical studies, to navigating late-stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success. The company operates state-of-the-art development and manufacturing facilities in Europe and, as part of the CJ CheilJedang global family, is building a strong position in global health with its strategic partners worldwide.

For more information, visit www.bataviabiosciences.com

About CJ CheilJedang
CJ CheilJedang(CJCJ), the largest and major affiliate of CJ Group, is one of the leading & innovative company in food and biotechnology businesses in Korea. CJCJ’s consolidated revenue in 2023 reached USD 22.2 billion, with operating income of USD 1 billion. Established in 1953 as a food ingredient company, CJ CheilJedang has expanded its business to processed foods, feed & food additives, and most recently microbiome based therapeutics.

For more information, visit https://www.cj.co.kr/en/index

About Vaccine Biotechnology City (VBC)
For more information, visit www.vbc-vaccines.com